Summary：**MindRank Raises $52 Million Series B, Accelerating Cutting‑Edge AI Development** *Funding to adva

**MindRank Raises $52 Million Series B, Accelerating Cutting‑Edge AI Development**
*Funding to advance MindRank’s AI‑native drug R&D engine and innovative pipeline, including MDR‑001, an oral small‑molecule GLP‑1 receptor agonist in Phase III clinical development in China*
HANGZHOU, China, July 09, 2026 (GLOBE NEWSWIRE) — MindRank AI Ltd. (“MindRank”) announced today the close of a $52 million Series B financing round led by prominent venture capital firms and strategic biotech investors. The infusion of capital will turbocharge the company’s AI‑driven drug discovery platform and push its lead candidate, MDR‑001, toward regulatory approval in the Chinese market.

### Key Developments
The new round brings MindRank’s total funding to over $80 million since its inception in 2021. Proceeds will be allocated to three core areas: expanding the AI‑native R&D engine that integrates generative chemistry with predictive biology, scaling manufacturing capabilities for MDR‑001, and advancing additional pipeline assets targeting metabolic and oncologic indications. MDR‑001, an oral small‑molecule GLP‑1 receptor agonist, has completed Phase II trials with promising glucose‑lowering and weight‑management profiles and is now enrolling patients in a pivotal Phase III study across multiple sites in China. MindRank also disclosed a collaboration with a leading academic hospital to validate real‑world outcomes using its AI‑powered clinical trial optimization tools.

### Industry Analysis
The intersection of artificial intelligence and pharmaceutical research is reshaping how new medicines are conceived. Traditional drug discovery cycles often exceed a decade and cost upwards of $2 billion; AI platforms promise